Influenza Vaccine Enhancement with Immunomodulating Peptide Thymosin Alpha 1 - Clinical studies have shown that treatment with thymosin alpha 1 increases response to vaccination. - BioPharm


Influenza Vaccine Enhancement with Immunomodulating Peptide Thymosin Alpha 1
Clinical studies have shown that treatment with thymosin alpha 1 increases response to vaccination.

BioPharm International Supplements

18. Thurman GB, Seals C, Low TLK, Goldstein AL. Restorative effects of thymosin polypeptides on purified protein derivative-dependent migration inhibition factor production by the peripheral blood lymphocytes of adult thymectomized guinea pigs. J Biological Response Modifiers. 1984;3(2):160–173.

19. Ershler W, Hebert J, Blow A, Granter S, Lynch J. Effect of thymosin alpha one on specific antibody response and susceptibility to infection in young and aged mice. Int J Immunopharmacol. 1985;7:465–71.

20. Ershler W, Moore A, Socinski M. Influenza and aging: age-related changes and the effects of thymosin on the antibody response to influenza vaccine. J Clin Immunol. 1984;4:445–54.

21. Effros RB, Casillas A, Walford RL. The effect of thymosin alpha 1 on immunity to influenza in aged mice. In: Aging: Immunology and Infectious Disease: Mary Ann Liebert, Inc; 1988. p. 31–40.

22. Romani L, Bistoni F, Perruccio K, Montagnoli C, Gaziano R, Bozza S, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006;108(7):2265–74.

23. Shrivastava P, Singh SM, Singh N. Effect of thymosin alpha 1 on the antitumor activity of tumor-associated macrophage-derived dendritic cells. J Biomed Sci. 2004;11(5):623–30.

24. Osheroff PL. The effect of thymosin on glucocorticoid recepters in lymphoid cells. Cellular Immunol. 1981;60:376–85.

25. Baumann CA, Badamchian M, Goldstein AL. Thymosin alpha 1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways. Mech Age Develop. 1997;94:85–101.

26. D'Agostini C, Palamara AT, Favalli C, Sivilia M, Febbraro G, Bue C, et al. Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus. Int J Immunopharmacol. 1996;18(2):95–102.

27. Rasi G, Silecchia G, Sinibaldi-Vallebona P, Spaziani E, Pierimarchi P, Sivilia M, et al. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int J Cancer. 1994;57:701–5.

28. Pica F, Fraschetti M, Matteucci C, Tuthill C, Rasi G. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Anticancer Research. 1998;18:3571–78.

29. Hadden JW, Saha A, Sosa M, Hadden EM. Immunotherapy with natural interleukins and/or thymosin alpha 1 potently augments T-lymphocyte responses of hydrocortisone-treated aged mice. Int J Immunopharmacol. 1995;17(10):821–28.

30. Shrivastava P, Singh SM, Singh N. Antitumor activation of peritoneal macrophages by thymosin alpha-1. Cancer Invest. 2005;23(4):316–22.

31. Sjogren MH. Thymalfasin: an immune system enhancer for the treatment of liver disease. J Gastroenterol Hepatol. 2004;19(12):S69–72.

32. Bozza S, Gaziano R, Bonifazi P, Zelante T, Pitzurra L, Mongagnoli C, et al. Thymosin alpha 1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo. Int Immunol. 2007;19:1261–70.

33. Giuliani C, Napolitano G, Mastino A, Di Vincenzo S, D'Agostini C, Grelli S, et al. Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur J Immunol. 2000;30(3):778–86.

34. Romani L, Bistoni F, Gaziano R, Bozza S, Montagnoli C, Perruccio K, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004;103(11):4232–9.

blog comments powered by Disqus



Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here